8月21日，BioNTech SE盘中上涨5.69%，报117.2美元/股，成交额5462.5万美元。
消息面上，Moderna与默沙东联合研发的全球首个mRNA个性化癌症疫苗此前在III期临床试验中取得阳性结果，被视为mRNA技术平台在肿瘤治疗领域的历史性突破。该事件持续提振mRNA板块情绪，同行业Moderna当日仍上涨12.07%。BioNTech作为全球领先的mRNA技术平台公司，市场对其核心技术路线在癌症免疫治疗中的拓展前景持续看好，股价延续强势。BioNTech SE专注于结合免疫学与mRNA等尖端治疗平台，开发针对癌症和其他疾病的个体化免疫疗法。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.